LAUSR

inhaled corticosteroid (iCs) treatment used to effectively manage moderate to severe asthma. Multiple studies have raised concerns over adrenal suppression with iCs use, with conflicting findings. a new study in Nature Medicine investigated this issue in individuals with prevalent asthma by using large-scale metabolomic profiling of plasma. leveraged data from over 14,000 individuals from four independent epidemiological cohort studies: the ePiC-Norfolk cohort, the MGBB-asthma cohort, the CaMP randomized clinical trial (rCt) and the eMr-Cortisol cohort. these data were used to identify 17 endogenous steroid metabolites that were significantly decreased in individuals with prevalent asthma. these included two key hypo-thalamic–pituitary–adrenal axis DHea-s and cortisol, whose is a biomarker for adrenal note,